Cohort study of bevacizumab in combination with XELOX for metastatic colorectal cancer
Not Applicable
- Conditions
- Colorectal Cancer
- Registration Number
- JPRN-UMIN000003416
- Lead Sponsor
- Sano Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1.Synchronous or metachronous multiple cancers 2. Contraindication of bevacizumab oxaliplatin and capecitabine 3.Investigators considers not suitable for the study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ORR; overall response rate drug administration situation (drug compliance situation, post-treatment, etc )
- Secondary Outcome Measures
Name Time Method liver resection rate R0 liver resection rate TTF:time to treatment-failure PFS:progression-free survival OS :Overall survival adverse effects